[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515236":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":36,"responsibleParty":54,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Guangzhou 8th People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ART combined with interferon group",null,"The treatment protocol is ART combined with pegylated interferon α-2b injection. The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week. Follow-up times are at baseline, and during treatment at weeks 4, 8, 12, 24, 36, 48, 60, and 72.",[13],"Drug: Peginterferon alfa-2b Injection",{"label":15,"type":10,"description":16,"interventionNames":10},"ART group","Continuously using ART treatment, without the use of interferon. Follow-up times are at baseline, and during treatment at weeks 12, 24, 36, 48, 60, and 72.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Peginterferon alfa-2b Injection","The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.",[9],[24],{"name":25,"affiliation":26,"role":27},"Linghua Li, PhD","Guangzhou Eighth People's Hospital","STUDY_CHAIR",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+862083710825","llheliza@126.com",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"Yaozu He, Master","hyzdyl99@163.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Guangzhou Eighth People's Hospital, Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52,53],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Linghua LI","Chief physician","100515236","functional-cure-of-hepatitis-b-in-hivhbv-co-infected-patients-100515236",false,"NCT05988879","Functional Cure of Hepatitis B in HIV\u002FHBV Co-infected Patients","A Clinical Research on Functional Cure Strategies for Hepatitis B Among HIV\u002FHBV Co-infected Patients in China","Inclusion Criteria:\n\n1. Age 18-65 years old, gender unrestricted.\n2. Meeting the People's Republic of China Health Industry Standard (WS293-2008) - \"AIDS and HIV Infection Diagnostic Criteria\", confirmed as HIV-1 infected.\n3. HBsAg positive for more than 6 months.\n4. At least 1 year of ART treatment prior to screening, and currently undergoing ART treatment with HBsAg \\\u003C1000IU\u002FmL, HBeAg negative, HBV DNA \\\u003C100IU\u002Fml, CD4+T lymphocyte count \\>200 cells\u002FμL and HIV-RNA\\\u003C20 copies\u002Fml.\n\nExclusion Criteria:\n\n1. Pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy.\n2. Co-infected with Hepatitis A, C, D, or E viruses.\n3. With other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver.\n4. With autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus.\n5. Post organ transplant, planning organ transplant, diagnosed or suspected of liver cancer or other malignant tumors, or undergoing immunosuppressive treatment.\n6. With severe diseases of heart, lungs, kidneys, brain, retinal disorders, or uncontrolled hypertension or diabetes.\n7. Excessive alcohol (average daily alcohol intake \\>40g for men, \\>20g for women) or drug users.\n8. Participated in other interventional trials within the last three months, or other situations deemed inappropriate for inclusion by researchers.","ALL","18 Years","65 Years",{"count":69,"type":70},60,"ESTIMATED","OBSERVATIONAL","Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV\u002FHBV co-infected patients",[74,75],"AIDS","Hepatitis B",[77,78,79],"HIV\u002FHBV co-infection","Functional cure","Interferon","2023-08-10",{"date":82,"type":83},"2023-08-14","ACTUAL",{"date":85,"type":83},"2023-08-02",{"date":87,"type":70},"2028-08-02",{"name":5,"class":6},1]